G. Bothamley (London, United Kingdom), I. Kontsevaya (Borstel, Germany)
This session is built from abstracts published on the ERS Congress platform from 23 August, in an e-poster pdf format with a 3-minute audio narration. Participants and chairs of the session are invited to access all e-posters from 23 August to 4 September prior to the 1-hour live, online discussion scheduled from September 5-7. Please note that during live discussion there will be NO e-poster/abstract presentations, only discussion.
Impact of COVID-19 and lockdown on TB care
L. Rusakova (Moscow, Russian Federation), S. Sterlikov (Moscow, Russian Federation), D. Kucheryavaya (Moscow, Russian Federation)
|   |
Species-specific Interferon-Gamma Release Assay for the diagnosis of Mycobacterium abscessus complex infection in Cystic Fibrosis patients.
M. Steindor (Essen, Germany), F. Stehling (Essen, Germany), M. Olivier (Essen, Germany), J. Kehrmann (Essen, Germany), M. Diricks (Borstel, Germany), F. Maurer (Borstel, Germany), P. Horn (Essen, Germany), S. Straßburg (Essen, Germany), M. Welsner (Essen, Germany), S. Sutharsan (Essen, Germany), M. Lindemann (Essen, Germany)
| |
Pulmonary tuberculosis control: does COVID-19 have any effect?
A. Gigante (Vila Nova de Gaia, Portugal), M. Sousa (Vila Nova de Gaia, Portugal), A. Aguiar (Porto, Portugal), M. Pinto (Porto, Portugal), R. Gaio (Porto, Portugal), R. Duarte (Vila Nova de Gaia; Porto, Portugal)
| |
Co-infection of pulmonary tuberculosis and Covid-19
Z. Laushkina (Novosibirsk, Russian Federation)
| |
Assessment of COVID-19 impact on the course of pulmonary tuberculosis
E. Shishkina (Moscow, Russian Federation), L. Ergeshova (Moscow, Russian Federation), A. Egorova (Moscow, Russian Federation), N. Evseeva (Moscow, Russian Federation), T. Smirnova (Moscow, Russian Federation), N. Karpina (Moscow, Russian Federation)
| |
Impact of COVID-19 on TB management in an East London Hospital
A. Rahman (London, United Kingdom), D. Braier-Lorimer (London, United Kingdom), F. Sinead (London, United Kingdom), S. Tiberi (London, United Kingdom), R. Khaw (London, United Kingdom), K. Heinke (London, United Kingdom)
| |
The impact of SARS-CoV-2 pandemic on tuberculosis – the experience of Iasi County, Romania
I. Grosu-Creanga (Iasi (Iasi), Romania), A. Sorete Arbore (Iasi (Iasi), Romania)
| |
Tuberculosis/SARS-CoV-2 Co-infection: a Case Series
M. Silva (Recife, Brazil), L. Macedo-Farsoun (Recife, Brazil), B. Markman-Filho (Recife , Brazil), M. Lima-Filho (Recife, Brazil), K. Veiga (Recife, Brazil), M. Costa (Recife, Brazil), M. Athayde (Recife, Brazil), C. Luna (Recife, Brazil)
| |
Frequency of chronic pulmonary aspergillosis in patients treated for pulmonary tuberculosis at a tertiary care hospital in Karachi, Pakistan.
S. Zubair (karachi, Pakistan), K. Jabeen (karachi, Pakistan), M. Irfan (karachi, Pakistan)
| |
Screening for tuberculosis in patients with COVID-19 infection in Georgia.
N. Kiria (Tbilisi, Georgia), Z. Avaliani (Tbilisi, Georgia), M. Eristavi (Tbilisi, Georgia), M. Shurgaia (Tbilisi, Georgia), L. Mikiashvili (Tbilisi, Georgia)
| |
The impact of COVID-19 sanitary measures on tuberculosis outbreaks
D. Monteiro Canhoto (Coimbra, Portugal), B. Ramos (Coimbra, Portugal), A. Ferreira (Coimbra, Portugal), P. Cravo Roxo (Coimbra, Portugal)
| |
COVID19 coinfection exacerbates lung inflammation in TB patients.
G. Shepelkova (Moscow, Russian Federation), V. Evstifeev (Moscow, Russian Federation), R. Tarasov (Moscow, Russian Federation), V. Aliev (Moscow, Russian Federation), M. Bagirov (Moscow, Russian Federation), Y. Berezovskiy (Moscow, Russian Federation), M. Isaeva (Moscow, Russian Federation), V. Yeremeev (Moscow, Russian Federation)
| |
Adverse events in the treatment of patients with pulmonary tuberculosis combined with diabetes mellitus and without it.
O. Komissarova (Moscow, Russian Federation), R. Abdullaev (Moscow, Russian Federation), S. Aleshina (Moscow, Russian Federation)
| |
A COMPARATIVE STUDY ON EFFECTS OF SUBSTANCE DEPENDENCE ON PULMONARY TUBERCULOSIS PATIENTS
M. Mukherjee (Kolkata, India), S. Kundu (Kolkata, India), R. Basu (Kolkata, India)
| |
The influence of SARS-CoV-2 co-infection and active tuberculosis on the severity of the disease course and mortality.
G. Przybylski (Osielsko, Poland), A. Kozanecka (Bydgoszcz, Poland), M. Pilaczynska-Cemel (Bydgoszcz, Poland)
| |
Characteristics of tuberculosis patients co-infected with COVID-19
E. Bogorodskaya (Moscow, Russian Federation), S. Borisov (Moscow, Russian Federation), E. Belilovskiy (Moscow, Russian Federation), E. Sumarokova (Moscow, Russian Federation), O. Chizhova (Moscow, Russian Federation)
| |
Taking care of TB in times of COVID-19 Global Pandemic
J. Garcia Fuertes (Vitoria-Gasteiz, Spain), N. Martin Lería (Vitoria-Gasteiz, Spain), J. Poyo Molina (Vitoria-Gasteiz, Spain), M. Sanchez De Toro (Vitoria-Gasteiz, Spain), I. Elorza Sagasta (Vitoria-Gasteiz, Spain), C. Ortega Michel (Vitoria-Gasteiz, Spain), L. Tomás López (Vitoria-Gasteiz, Spain), M. Lahidalga Múgica (Vitoria-Gasteiz, Spain), J. Portu Zapirain (Vitoria-Gasteiz, Spain), S. Hernaez Crespo (Vitoria-Gasteiz, Spain), A. Canut Blasco (Vitoria-Gasteiz, Spain), J. Lobo Beristain (Vitoria-Gasteiz, Spain)
| |
Particularities of pulmonary tuberculosis during the COVID-19 pandemic
K. Hemissi (tunis, Tunisia), E. Ben Jemia (Tunis, Tunisia), H. Zaibi (Tunis, Tunisia), M. Mosbeh (Tunis, Tunisia), A. Allouch (Tunis, Tunisia), K. Euchi (Tunis, Tunisia), J. Ben Ammar (Tunis, Tunisia), H. Aouina (Tunis, Tunisia)
| |
Burden of co-morbid conditions in TB patients attending a tertiary care hospital in India
D. Christopher (Vellore (Tamil Nadu), India), B. Isaac (Vellore, India), A. Arjun (Vellore, India), D. Shankar (Vellore, India), B. Thangakunam (Vellore (Tamil Nadu), India)
| |
Mesodiencephalic modulation in the treatment of XDR TB patients with concomitant type II diabetes mellitus
A. Polyakova (Moscow, Russian Federation), M. Tihonova (Moscow, Russian Federation), V. Romanov (Moscow, Russian Federation), A. Tihonov (Moscow, Russian Federation), N. Chernyh (Moscow, Russian Federation)
| |